Patients with RET fusion-positive NSCLC treated with RET-TKIs can achieve longer disease-free survival, indicating that RET-TKIs have a good effect on these patients, which may be related to the high specificity of Pralsetinib and Selpercatinib for RET. This evidence concerns the gene RET and non-small cell lung carcinoma.